Related Experiment Video
Updated: Sep 10, 2025
ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
Published on: February 10, 2017
Efficacy of endoscopic intermuscular dissection vs. endoscopic submucosal dissection in treating rectal
Guang Yang1, Jingsong Wang1, Bo Li1
1South China Hospital Affiliated to Shenzhen University, Shenzhen, China.
Background And Study Aims:
Rectal neuroendocrine tumors (r-NETs) exhibit significant heterogeneity and malignant potential. Currently, endoscopic resection is the preferred treatment for r-NETs < 10 mm. However, traditional endoscopic resection carries a risk of positive vertical margins. This study aimed to compare clinical efficacy of endoscopic intermuscular dissection (EID) and endoscopic submucosal dissection (ESD) in treating small r-NETs (< 10 mm).
Patients And Methods:
This retrospective study included 56 patients with r-NETs < 10 mm who underwent endoscopic treatment between April 2017 and September 2024 at Shenzhen University Affiliated South China Hospital and Shenzhen Hospital of Southern Medical University. All procedures were performed by the same surgeon. Patients were divided into two groups based on type of endoscopic treatment: the EID group (n = 16) and the ESD group (n = 40). We compared operative time, technical success rates, resection outcomes, adverse event (AE) rates, and histopathological findings between the two groups.
Results:
Median lesion size in the EID group (7.5 mm) was significantly larger than in the ESD group (6.0 mm) ( P = 0.001). Although operative time in the EID group was longer (39 vs 28.5 minutes), the difference was not statistically significant ( P = 0.137). The complete resection rate was 100% in the EID group and 97.5% in the ESD group, with no statistically significant difference. There were no significant differences in general characteristics, technical success rates (100% vs 100%), or incidence of AEs (bleeding, perforation, infection) (0% vs 0%) between groups ( P > 0.05).
Conclusions:
Endoscopic intermuscular dissection offers a better option for preventing positive basal margins and demonstrates good safety and feasibility.
Insights
Endoscopic intermuscular dissection (EID) is a safe and effective treatment for small rectal neuroendocrine tumors (r-NETs), achieving 100% complete resection rates. This method shows promise in preventing positive basal margins, offering a valuable alternative to endoscopic submucosal dissection (ESD).
Area of Science:
- Gastroenterology
- Surgical Oncology
- Endoscopic Procedures
Background:
- Rectal neuroendocrine tumors (r-NETs) present heterogeneity and malignant potential.
- Current standard treatment for small r-NETs (<10 mm) is endoscopic resection.
- Traditional methods risk positive vertical margins, necessitating improved techniques.
Purpose of the Study:
- To compare the clinical efficacy of endoscopic intermuscular dissection (EID) and endoscopic submucosal dissection (ESD).
- To evaluate outcomes for small rectal neuroendocrine tumors (<10 mm).
Main Methods:
- Retrospective study of 56 patients with r-NETs (<10 mm).
- Comparison between EID (n=16) and ESD (n=40) groups.
- Analysis of operative time, success rates, resection outcomes, and adverse events.
Main Results:
- Complete resection rates were 100% for EID and 97.5% for ESD (no significant difference).
- No significant differences in technical success (100% vs 100%) or adverse events (0% vs 0%).
- Median lesion size was larger in the EID group (7.5 mm) vs ESD group (6.0 mm).
Conclusions:
- Endoscopic intermuscular dissection (EID) is a safe and feasible option for small r-NETs.
- EID demonstrates potential for preventing positive basal margins.
- EID offers a comparable alternative to ESD for selected rectal neuroendocrine tumors.
More Related Videos
03:54A New Ex Vivo Model for the Evaluation of Endoscopic Submucosal Injection Material Performance
Published on: October 19, 2018
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022